We help you understanding patient needs with a customized mix of approaches.

Technology combined with unmatched patient engagement services to create successful patient recruitment strategies, trial awareness and boosted enrollment

While there has been a centralized European marketing authorization procedure for years, Health Technology Assessments (HTA) remained decentralized at state level – this will change with the EU regulation (2021/2282) on HTA.

Dr. Blaschek, a doctor from a Neuromuscular Center certified by the German Muscular Society (DGM), answers the questions of parents and patients in the video.

The European Alliance for Newborn Screening in Spinal Muscular Atrophy (SMA NBS Alliance) was founded in 2020 by SMA Europe and a group of diverse stakeholders.

admedicum is proud to support the European Alliance for Spinal Muscular Atrophy Newborn Screening in its role as the Secretariat.

Patients with rare or complex diseases are often overwhelmed when it comes to finding their way in the healthcare system.

REFER is a project from the Innovative Medicines Initiative (IMI). “IMI is the world’s biggest public-private partnership in the life sciences.

In a number of projects admedicum and Justin Stindt Consulting have already successfully merged their expertise. The companies now are combining their skills tighter to create value for both patients and industry.

It’s time for Europe to bridge the gap in newborn screening for spinal muscular atrophy. The European Alliance for Newborn Screening in Spinal Muscular Atrophy calls upon the government of Europe to include a test for SMA in national newborn screening programmes.

The patient association MPS España and the patient engagement expert group admedicum Business for Patients are excited to announce their strategic partnership.